01.05.25 Investissement Québec Release
Gouvernement du Québec, Seido Capital and Anges Québec combine to provide Innospera with $5M seed financing
MONTREAL, Quebec, Canada – May 1, 2025 – Investissement Québec, acting as trustee of the gouvernement du Québec, Anges Quebec and Seido Capital announced they have recently jointly invested in a $5 million financing in Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company focused on developing small-molecule GPCR modulators to address a broad range of inflammatory and metabolic diseases with high unmet medical needs.
“The gouvernement du Québec, Seido Capital, and Anges Québec worked synergistically together to support Innospera’s vision, based on the strong potential of our lead assets,” noted Pierre Laurin, Executive Chairman of the Board of Innospera. “We are privileged to work in one of the best life science clusters in North America, where innovation is recognized by quality investors, acting together as catalysts for promising endeavours like ours.”
“Investissement Québec is proud to support Innospera’s growth through the Impulsion PME program, as the Company gets closer to clinical stage. Québec life science industry stands out with innovative and vibrant stakeholders,” noted Bicha Ngo, president and chief executive officer, Investissement Québec.
“Pierre and the Innospera team have a clear vision of the multiple medical unmet needs that could benefit from their science, starting by idiopathic pulmonary fibrosis, and we are engaged with them to this end” completed Patricia Escoffier, principal, Seido Capital.
“Anges Québec’s investors are always looking for the best opportunities to support smart innovation, especially at early-stage,” added Hélène Moore, lead angel on the Innospera investment. “Innospera has all it needs to become a promising clinical-stage company in Québec’s flourishing biotech cluster.”
About Long-term Inflammation
Systemic inflammation (inflammaging), increases as a consequence of aging contributing to age-related morbidities. Persistent activation of fibrotic pathways and organ dysfunction is markedly more frequent in the elderly (fibroaging). Elderly individuals with chronic disorders tend to develop inflammaging, a condition associated with elevated levels of blood inflammatory markers and increased susceptibility to chronic disease progression. Chronic, low-grade inflammation is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the lung, kidney, heart, liver, nervous and the musculoskeletal system.
About Innospera
Innospera is a Montreal-based, privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range of chronic and fibrotic conditions. The company’s lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary fibrosis (IPF), a condition with dire short-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs.
About Investissement Québec
Investissement Québec’s mission is to play an active role in Quebec’s economic development by stimulating business innovation, entrepreneurship, and business acquisitions, as well as growth in investment and exports. Operating in all the province’s administrative regions, the Corporation supports the creation and growth of businesses of all sizes with investments and customized financial solutions. It also assists businesses by providing consulting services and other support measures, including technological assistance available from Investissement Québec Innovation. In addition, through Investissement Québec International, the Corporation prospects for talent and foreign investment, and assists Quebec businesses with export activities. For more information, visit investquebec.com
About Seido Capital
Seido Capital is a Montreal-based venture capital firm specializing in pre-seed, seed, and startup investments in the life sciences sector. With a strong focus on the convergence of AI, software, and the biopharmaceutical industry, Seido Capital aims to promote innovation across North America by partnering with visionary entrepreneurs to foster technologies that make a real difference. For more information, visit seidocapital.com
About Anges Québec
As Canada’s largest angel investors group, Anges Québec has been supporting passionate and innovative entrepreneurs for 15 years. With over 200 members from diverse backgrounds, we have invested nearly $148 million in more than 200 Quebec tech companies, in partnership with the AQC Capital fund. We’re proud to play a leading role in the venture capital industry in Quebec by actively supporting local innovation. For more information, visit angesquebec.com
Contact